NRG1 Expression Measurement for ERBB3 Inhibitor Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments with targeted therapies face challenges due to genetic variations among tumors, leading to variable patient responses, and there is a lack of efficient strategies to identify patients who would benefit from specific drugs, hindering the full potential of these therapies.
Innovation Solution
Measuring neuregulin-1 (NRG1) expression in tumor tissue samples to determine a tumor's sensitivity to ERBB3 inhibitors, using methods such as quantitative PCR or immunohistochemistry, and comparing the NRG1 score against a threshold to predict treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted therapies are used to treat cancer, then treatment effectiveness is improved for some patients, but variable patient response occurs due to genetic variation among tumors
Solution Approach 1:
The patent applies preliminary action by measuring NRG1 expression levels in tumor tissue samples before initiating anti-ERBB3 antibody treatment. This pre-treatment biomarker assessment allows clinicians to predict which patients are most likely to respond to the therapy, enabling selective patient enrollment and avoiding ineffective treatments. The method performs the diagnostic action in advance to guide subsequent therapeutic decisions.
2Productivity
If biomarker discovery is accelerated to identify suitable patients, then clinical trial efficiency is improved, but the lack of efficient evaluation strategies currently limits this potential
Solution Approach 1:
The patent applies the taking out principle by extracting and focusing on a single critical biomarker (NRG1 expression) that predicts response to anti-ERBB3 therapy. Rather than requiring complex multi-gene panels or sophisticated evaluation systems, the invention isolates the most important predictive factor, simplifying the diagnostic workflow while maintaining high predictive accuracy. This extraction approach reduces complexity while improving clinical trial efficiency.
3Measurement precision
If NRG1 expression is measured to predict tumor sensitivity, then treatment selection accuracy is improved, but additional diagnostic testing requirements increase
Solution Approach 1:
The patent applies mechanics substitution by replacing complex functional assessments of tumor sensitivity with a straightforward molecular measurement of NRG1 expression levels. Instead of requiring complex in vitro sensitivity testing or multiple biomarker evaluations, the invention substitutes these mechanical/functional assays with a simpler molecular biology-based measurement (mRNA or protein quantification), achieving high precision with reduced complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the accurate classification of tumors as sensitive or resistant to ERBB3 inhibitor treatment, enabling personalized treatment decisions and potentially improving treatment outcomes by identifying suitable candidates for targeted therapies.
Implementation Method 1
ERBB3 is the target for AV-203, and AV-203 blocks the binding of neuregulin-1 (NRG1) to ERBB3, thereby blocking downstream signaling
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.